Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcom...

The Usage-Based Insurance (UBI) market has now reached over 60 million customers across 450 active programmes – a sixfold increase in just ten years. PTOLEMUS Consulting Group, which predicted the “uberisation” of insurance in 2015, highlights this transformation in its new report. UBI is now a truly global phenomenon that reaches 59 countries and generates more than €50 billion in premiums, finds the consulting firm in its new report. This growth reflects the growing smartphonisation of th...